Advertisement

Long-Term Management of Prolactinomas—Use of Long-Acting Dopamine Agonists

  • David M. Cook
Original Article

Key Words

prolactinomas dopamine agonists 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Vallette-Kasic S, Morange-Ramos I, Selim A, Gunz G, Morange S, Enjalbert A, Martin PM, Jaquet P, Brue T. Macroprolactinemia revisted: A study on 106 patients. J Clin Endocrinol Metab 2002;87(2):581–581.CrossRefPubMedGoogle Scholar
  2. 2.
    Smith TP, Suliman AM, Fahie-Wilson MN, McKenna TJ. Gross variablility in the detection of prolactin in sera containing big prolatin (macroprolactin) by commercial immunoassays. J Clin Endocrinol Metab 2002;87(12):5410–5410.CrossRefPubMedGoogle Scholar
  3. 3.
    Schlechte JA. The macroprolactin problem. J Clin Endocrinol Metab 2002;87(12):5408–5408.CrossRefPubMedGoogle Scholar
  4. 4.
    Guay AT, Sabharwal P, Varma S, Malarkey WB. Delayed diagnosis of psychological erectile dysfunction because of the presence of macroporlactinemia. J Clin Endocrinol Metab 1996;(81)2512–2514.Google Scholar
  5. 5.
    Leslie H, Courtney CH, Bell PM, Hadden DR, McCance DR, Ellis PK, Sheridan B, Atkinson AB. Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method. J Clin Metab 2001;86:2743–2746.Google Scholar
  6. 6.
    Vallette-Kasic S, Marange-Ramos I, Selim A, Gunz G, Morange S, Enjalbert A, Martin PM, Jaquet P, Brue T. Macroprolactinemia Revisited: A study on 106 patients. J Clin Endocrinol Metab 2002;87(2):581–581.CrossRefPubMedGoogle Scholar
  7. 7.
    Bevan JS, Burke CW, Esiri MM, Adams CBT. Misinterpretation of prolactin levels leading to management errors in patients with sellar enlargement. Am J Med 1987;82:29–32.CrossRefPubMedGoogle Scholar
  8. 8.
    St-Jean E, Blain F, Comtois R. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clin Endocrinol 1996;44:305–309.CrossRefGoogle Scholar
  9. 9.
    Barkan Al, Chandler WF. Giant pituitary prolactinoma with falsely low serum prolactin: The pitfall of the “high-dose hook effect”: Case report. Neurosurgery 1998;42:913–915.PubMedGoogle Scholar
  10. 10.
    Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A. The natural history of untreated hyperprolactinemia: A prospective analysis. J Clin Endocrinol Metab 1989;68:412–418.PubMedGoogle Scholar
  11. 11.
    Von Werder K, Eversmann T, Fahlbusch R, et al. Development of hyperprolactinemia in patients with and with out prior operative treatment. Excerpta Med Int Congr Ser 1982;584:175–188.Google Scholar
  12. 12.
    March CM, Kletzky OA, Davajan V, Teal J, Weiss M, Apuzzo ML, Marrs RP, Mishell DRJr. Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas. Am J Obstet Gynecol 1981;139:835–844.PubMedGoogle Scholar
  13. 13.
    Weiss MH, Teal J, Gott P, Wycoff R, Yadley R, Apuzzo ML, Giannotta SL, Kletzky O, March C. Natural history of microprolactinomas: Six-year follow-up. Neurosurgery 1983;12:180–183.PubMedGoogle Scholar
  14. 14.
    Koppelman MC, Jaffe MJ, Fieth KG, Caruso RC, Loriaux DL. Hyperprolactinemia, amenorrhea, and galactorrhea. Ann Intern Med 1984;100:115–121.PubMedGoogle Scholar
  15. 15.
    Sisam DA, Sheehan JP, Sheeler LR. The natural history of untreated microprolactinomas. Fertil Steril 1987;48:67–71.PubMedGoogle Scholar
  16. 16.
    Jeffcoate WJ, Pound N, Sturrock ND, Lambourne J. Long-term follow-up of patients with hyperprolactinaemia. Clin Endocrinol 1996;45:299–303.CrossRefGoogle Scholar
  17. 17.
    Wingrave SJ, Kay CR, Vessey MP. Oral contraceptives and pituitary adenomas. BMJ 1980;1:685–686.Google Scholar
  18. 18.
    Corenbulum B, Donovan L. The safety of physiological estrogen plus progestin replacement therapy with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil Steril 1993;59:671–673.Google Scholar
  19. 19.
    De Rosa M, Zarrilli S, Vitale G, Di Somma C, Orio F, Tauchmanova’L, Lombardi G, Colao A. Six months of treatment with cabergoline restores sexual potency in hyperprolacinemic males: An open longitudinal study monitoring nocturnal penile tumescence. J Clin Endocrinol Metab 2004;89(2):621–621.CrossRefPubMedGoogle Scholar
  20. 20.
    Webster J, Piscitelli G, Plli A, Ferrari C, Ismail I, Scanlon M. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. 1994;331:904–909.Google Scholar
  21. 21.
    Verhelst J, Abs R, Maiter D, Van Den Bruel A, Vandeweghe M, Belkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A. Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients. J Clin Endocrinol Metab 1999;84(7):2518.CrossRefPubMedGoogle Scholar
  22. 22.
    Molitch ME. Prolactinomas. In: Melmed S, ed. The Pituitary. Cambridge, MA, Balckwell Science, Inc., 1995:443–443.Google Scholar
  23. 23.
    Freda PU, Andreadis CI, Khandji AG, Khoury M, Bruce JN, Jacobs P, Wardlaw SL. Long-term treatment of Prolactin-Secreting Macroadenomas with Pergolide. J Clin Endocrinol Metab 2000;85(1):8.CrossRefPubMedGoogle Scholar
  24. 24.
    Colao An, Bitale G, Cappabianca P, Briganti F, Ciccarelli A, DeRosa M, Zarrilli S, Lonbardi G. Outcome of Cabergoline treatment in men with Prolactinoma: Effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clinc Endocrinol Metab 2003;89(4):1704–1704.Google Scholar
  25. 25.
    Colao A, De Sarno A, Landi M, Scavuzzo F, Cappabianca P, Pivonello R, Annunziato G, Lombardi G. Macroprolactinoma shrinkage during cabergoline treatment is greater in naïve patients than in patients pretreated with other dopamine agonists: A prospective study in 110 patients. J Clinc Endocrinol Metab 2000;85(6):2247.Google Scholar
  26. 26.
    Colao A, De Sarno A, Landi M, Scavuzzo F, Cappabianca P, Pivonello R, Annunziato G, Lombardi G. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clinc Endocrinol Metab 1997;82(11):3574.Google Scholar
  27. 27.
    Biller B, Molitch M, Lee Vance M, Cannistraro K, Davis K, Simons J, Schoenfelder JR, Klibanski A. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clinc Endocrinol Metab 1996;81(6):2338.Google Scholar
  28. 28.
    Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. New Eng J Med 2003;349:2023–2033.PubMedGoogle Scholar
  29. 29.
    Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C, Beckers A. Cabergoline in the treatment of acromegaly: A study in 64 patients. J Clinc Endocrinol Metab 1998;83(2):374.Google Scholar
  30. 30.
    Gemzell C, Wang CF. Outcome of pregnancy in women with pituitary adenoma. Pertil Steril 1979;31:363–372.Google Scholar
  31. 31.
    Molitch ME. Pregnancy and the hyperprolactinemic woman. N Engl J Med 1985;312:1365–1370.Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2005

Authors and Affiliations

  • David M. Cook
    • 1
  1. 1.Oregon Health & Sciences University, EndocrinologyPortlandUSA

Personalised recommendations